NUVALENT INC-A (NUVL) Stock Fundamental Analysis

NASDAQ:NUVL • US6707031075

101.95 USD
-1.98 (-1.91%)
At close: Feb 27, 2026
101.95 USD
0 (0%)
After Hours: 2/27/2026, 8:23:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

NUVL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. NUVL has a great financial health rating, but its profitability evaluates not so good. NUVL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • NUVL had negative earnings in the past year.
  • In the past year NUVL has reported a negative cash flow from operations.
  • In the past 5 years NUVL always reported negative net income.
  • NUVL had a negative operating cash flow in each of the past 5 years.
NUVL Yearly Net Income VS EBIT VS OCF VS FCFNUVL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • NUVL has a Return On Assets of -38.93%. This is comparable to the rest of the industry: NUVL outperforms 58.81% of its industry peers.
  • The Return On Equity of NUVL (-45.12%) is better than 67.82% of its industry peers.
Industry RankSector Rank
ROA -38.93%
ROE -45.12%
ROIC N/A
ROA(3y)-19.01%
ROA(5y)-42.03%
ROE(3y)-20.02%
ROE(5y)-88.07%
ROIC(3y)N/A
ROIC(5y)N/A
NUVL Yearly ROA, ROE, ROICNUVL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • NUVL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVL Yearly Profit, Operating, Gross MarginsNUVL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • NUVL has more shares outstanding than it did 1 year ago.
  • NUVL has more shares outstanding than it did 5 years ago.
  • NUVL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NUVL Yearly Shares OutstandingNUVL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
NUVL Yearly Total Debt VS Total AssetsNUVL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 33.62 indicates that NUVL is not in any danger for bankruptcy at the moment.
  • NUVL has a better Altman-Z score (33.62) than 93.30% of its industry peers.
  • There is no outstanding debt for NUVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 33.62
ROIC/WACCN/A
WACCN/A
NUVL Yearly LT Debt VS Equity VS FCFNUVL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 10.73 indicates that NUVL has no problem at all paying its short term obligations.
  • NUVL has a better Current ratio (10.73) than 84.48% of its industry peers.
  • NUVL has a Quick Ratio of 10.73. This indicates that NUVL is financially healthy and has no problem in meeting its short term obligations.
  • NUVL's Quick ratio of 10.73 is amongst the best of the industry. NUVL outperforms 84.48% of its industry peers.
Industry RankSector Rank
Current Ratio 10.73
Quick Ratio 10.73
NUVL Yearly Current Assets VS Current LiabilitesNUVL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for NUVL have decreased strongly by -53.31% in the last year.
EPS 1Y (TTM)-53.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NUVL will show a very strong growth in Earnings Per Share. The EPS will grow by 22.61% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-50.14%
EPS Next 2Y-22.88%
EPS Next 3Y-4.05%
EPS Next 5Y22.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NUVL Yearly Revenue VS EstimatesNUVL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
NUVL Yearly EPS VS EstimatesNUVL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NUVL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVL Price Earnings VS Forward Price EarningsNUVL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVL Per share dataNUVL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as NUVL's earnings are expected to decrease with -4.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.88%
EPS Next 3Y-4.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NUVL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NUVALENT INC-A

NASDAQ:NUVL (2/27/2026, 8:23:24 PM)

After market: 101.95 0 (0%)

101.95

-1.98 (-1.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)03-04
Inst Owners100.99%
Inst Owner Change7%
Ins Owners0.5%
Ins Owner Change2.68%
Market Cap7.87B
Revenue(TTM)N/A
Net Income(TTM)-381.44M
Analysts85.83
Price Target142.67 (39.94%)
Short Float %8.52%
Short Ratio11.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.85%
Min EPS beat(2)-21.37%
Max EPS beat(2)-10.33%
EPS beat(4)1
Avg EPS beat(4)-8.47%
Min EPS beat(4)-21.37%
Max EPS beat(4)4.41%
EPS beat(8)2
Avg EPS beat(8)-10.19%
EPS beat(12)5
Avg EPS beat(12)-5.98%
EPS beat(16)8
Avg EPS beat(16)-3.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.01%
PT rev (3m)11.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.31
P/tB 9.31
EV/EBITDA N/A
EPS(TTM)-5.32
EYN/A
EPS(NY)-5.89
Fwd EYN/A
FCF(TTM)-3.42
FCFYN/A
OCF(TTM)-3.42
OCFYN/A
SpS0
BVpS10.95
TBVpS10.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.93%
ROE -45.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.01%
ROA(5y)-42.03%
ROE(3y)-20.02%
ROE(5y)-88.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.73
Quick Ratio 10.73
Altman-Z 33.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.81%
EPS Next Y-50.14%
EPS Next 2Y-22.88%
EPS Next 3Y-4.05%
EPS Next 5Y22.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-58.97%
EBIT Next 3Y-3.96%
EBIT Next 5Y17.18%
FCF growth 1Y-202.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-202.23%
OCF growth 3YN/A
OCF growth 5YN/A

NUVALENT INC-A / NUVL FAQ

What is the ChartMill fundamental rating of NUVALENT INC-A (NUVL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NUVL.


Can you provide the valuation status for NUVALENT INC-A?

ChartMill assigns a valuation rating of 0 / 10 to NUVALENT INC-A (NUVL). This can be considered as Overvalued.


What is the profitability of NUVL stock?

NUVALENT INC-A (NUVL) has a profitability rating of 1 / 10.


Can you provide the financial health for NUVL stock?

The financial health rating of NUVALENT INC-A (NUVL) is 8 / 10.